- Home
- EM vs ALDX Comparison
EM vs ALDX Comparison
Compare EM & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EM | ALDX |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.7M | 317.7M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | EM | ALDX |
|---|---|---|
| Price | $1.13 | $5.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $1.25 | ★ $9.50 |
| AVG Volume (30 Days) | 89.2K | ★ 708.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.30 | N/A |
| Revenue Next Year | $5.26 | $36.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $1.18 |
| 52 Week High | $1.46 | $7.19 |
Technical Indicators
Market Signals| Indicator | EM | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 37.90 | 48.36 |
| Support Level | $1.10 | $4.74 |
| Resistance Level | $1.18 | $5.70 |
| Average True Range (ATR) | 0.02 | 0.30 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 34.09 |
Price Performance
Historical ComparisonAbout EM Smart Share Global Limited
Smart Share Global Ltd is a consumer tech company providing mobile device charging services through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Geographically, the company generates revenue from the PRC. The company has two segments, the mobile device charging segment and the PV business segment. The company generates the majority of its revenue from the mobile device charging segment.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.